Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/65198
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRiga, Maurizio S.-
dc.contributor.authorSoria, Guadalupe-
dc.contributor.authorTudela Fernández, Raúl-
dc.contributor.authorArtigas Pérez, Francesc-
dc.contributor.authorCelada Pedrosa, Paz-
dc.date.accessioned2015-04-24T10:42:44Z-
dc.date.available2015-04-24T10:42:44Z-
dc.date.issued2014-03-20-
dc.identifier.issn1461-1457-
dc.identifier.urihttp://hdl.handle.net/2445/65198-
dc.description.abstract5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a natural hallucinogen component of Ayahuasca, an Amazonian beverage traditionally used for ritual, religious and healing purposes that is being increasingly used for recreational purposes in US and Europe. 5MeO-DMT is of potential interest for schizophrenia research owing to its hallucinogenic properties. Two other psychotomimetic agents, phencyclidine and 2,5-dimethoxy-4-iodo-phenylisopropylamine (DOI), markedly disrupt neuronal activity and reduce the power of low frequency cortical oscillations (<4 Hz, LFCO) in rodent medial prefrontal cortex (mPFC). Here we examined the effect of 5-MeO-DMT on cortical function and its potential reversal by antipsychotic drugs. Moreover, regional brain activity was assessed by blood-oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI). 5-MeO-DMT disrupted mPFC activity, increasing and decreasing the discharge of 51 and 35% of the recorded pyramidal neurons, and reducing (−31%) the power of LFCO. The latter effect depended on 5-HT1A and 5-HT2A receptor activation and was reversed by haloperidol, clozapine, risperidone, and the mGlu2/3 agonist LY379268. Likewise, 5-MeO-DMT decreased BOLD responses in visual cortex (V1) and mPFC. The disruption of cortical activity induced by 5-MeO-DMT resembles that produced by phencyclidine and DOI. This, together with the reversal by antipsychotic drugs, suggests that the observed cortical alterations are related to the psychotomimetic action of 5-MeO-DMT. Overall, the present model may help to understand the neurobiological basis of hallucinations and to identify new targets in antipsychotic drug development.-
dc.format.extent14 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherCambridge University Press-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1017/S1461145714000261-
dc.relation.ispartofInternational Journal of Neuropsychopharmacology, 2014, vol. 17, num. 8, p. 1269-1282-
dc.relation.urihttp://dx.doi.org/10.1017/S1461145714000261-
dc.rights(c) CINP (Collegium Internationale Neuro-Psychopharmacologicum) , 2014-
dc.subject.classificationAntipsicòtics-
dc.subject.classificationAl·lucinògens-
dc.subject.classificationReceptors de serotonina-
dc.subject.classificationEsquizofrènia-
dc.subject.otherAntipsychotic drugs-
dc.subject.otherHallucinogenic drugs-
dc.subject.otherSerotonin receptors-
dc.subject.otherSchizophrenia-
dc.titleThe natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec650995-
dc.date.updated2015-04-24T10:42:44Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
650995.pdf933.64 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.